Giuseppe De Luca1, Ettore Cassetti, Paolo Marino. 1. Division of Cardiology, Ospedale Maggiore della Carità, Eastern Piedmont University, C.so Mazzini, 18, 24100 Novara, Italy. giuseppe.deluca@maggioreosp.novara.it
Abstract
AIMS: Recent concerns have emerged on the potential higher risk of stent thrombosis after Drug-eluting stents (DES) implantation, that might be even more pronounced among ST-segment elevation myocardial infarction (STEMI) patients. The aim of the current study was to evaluate, by a meta-analytic approach, whether the benefits and safety of DES as compared to bare-metal stents (BMS) in patients undergoing primary angioplasty for STEMI may be influenced by the duration of prescription of dual oral antiplatelet therapy. METHODS: The literature was scanned by formal searches of electronic databases (MEDLINE and CENTRAL). We examined all completed randomized trials of DES for STEMI. The following key words were used for study selection: randomized trial, myocardial infarction, reperfusion, primary angioplasty, stenting, DES, sirolimus-eluting stent (SES), Cypher, paclitaxel-eluting stent (PES), Taxus. Information on study design, type of stent, inclusion and exclusion criteria, primary endpoint, number of patients, angiographic and clinical outcome, were extracted by two investigators. Disagreements were resolved by consensus. RESULTS: A total of 12 trials were included in the meta-analysis, involving 4,351 patients (2,260 or 51.9% randomized to DES and 2,091 or 48.1% randomized to BMS). In five trials (involving 1690 patients) dual oral antiplatelet therapy was prescribed for at least 1 year. The outcome of DES as compared to BMS was not affected by the duration of dual antiplatelet therapy in terms of death (P interaction = 0.16), reinfarction (P interaction = 0.91) and in-stent thrombosis (P interaction = 0.26) and TVR (P interaction = 0.38). These data were confirmed by the use of a meta-regression analysis. CONCLUSIONS: This meta-analysis shows that among selected STEMI patients undergoing primary angioplasty, DES (SES and PES), as compared to BMS, are safe and their benefits are not affected by the duration of clopidogrel prescription.
AIMS: Recent concerns have emerged on the potential higher risk of stent thrombosis after Drug-eluting stents (DES) implantation, that might be even more pronounced among ST-segment elevation myocardial infarction (STEMI) patients. The aim of the current study was to evaluate, by a meta-analytic approach, whether the benefits and safety of DES as compared to bare-metal stents (BMS) in patients undergoing primary angioplasty for STEMI may be influenced by the duration of prescription of dual oral antiplatelet therapy. METHODS: The literature was scanned by formal searches of electronic databases (MEDLINE and CENTRAL). We examined all completed randomized trials of DES for STEMI. The following key words were used for study selection: randomized trial, myocardial infarction, reperfusion, primary angioplasty, stenting, DES, sirolimus-eluting stent (SES), Cypher, paclitaxel-eluting stent (PES), Taxus. Information on study design, type of stent, inclusion and exclusion criteria, primary endpoint, number of patients, angiographic and clinical outcome, were extracted by two investigators. Disagreements were resolved by consensus. RESULTS: A total of 12 trials were included in the meta-analysis, involving 4,351 patients (2,260 or 51.9% randomized to DES and 2,091 or 48.1% randomized to BMS). In five trials (involving 1690 patients) dual oral antiplatelet therapy was prescribed for at least 1 year. The outcome of DES as compared to BMS was not affected by the duration of dual antiplatelet therapy in terms of death (P interaction = 0.16), reinfarction (P interaction = 0.91) and in-stent thrombosis (P interaction = 0.26) and TVR (P interaction = 0.38). These data were confirmed by the use of a meta-regression analysis. CONCLUSIONS: This meta-analysis shows that among selected STEMI patients undergoing primary angioplasty, DES (SES and PES), as compared to BMS, are safe and their benefits are not affected by the duration of clopidogrel prescription.
Authors: Christian Spaulding; Patrick Henry; Emmanuel Teiger; Kevin Beatt; Ezio Bramucci; Didier Carrié; Michel S Slama; Bela Merkely; Andrejs Erglis; Massimo Margheri; Olivier Varenne; Ana Cebrian; Hans-Peter Stoll; David B Snead; Christoph Bode Journal: N Engl J Med Date: 2006-09-14 Impact factor: 91.245
Authors: Gerrit J Laarman; Maarten J Suttorp; Maurits T Dirksen; Loek van Heerebeek; Ferdinand Kiemeneij; Ton Slagboom; L Ron van der Wieken; Jan G P Tijssen; Benno J Rensing; Mark Patterson Journal: N Engl J Med Date: 2006-09-14 Impact factor: 91.245
Authors: Deepak L Bhatt; Michel E Bertrand; Peter B Berger; Philippe L L'Allier; Issam Moussa; Jeffrey W Moses; George Dangas; Megumi Taniuchi; John M Lasala; David R Holmes; Stephen G Ellis; Eric J Topol Journal: J Am Coll Cardiol Date: 2002-01-02 Impact factor: 24.094
Authors: Bo Lagerqvist; Stefan K James; Ulf Stenestrand; Johan Lindbäck; Tage Nilsson; Lars Wallentin Journal: N Engl J Med Date: 2007-02-12 Impact factor: 91.245
Authors: Gregg W Stone; Stephen G Ellis; David A Cox; James Hermiller; Charles O'Shaughnessy; James Tift Mann; Mark Turco; Ronald Caputo; Patrick Bergin; Joel Greenberg; Jeffrey J Popma; Mary E Russell Journal: N Engl J Med Date: 2004-01-15 Impact factor: 91.245
Authors: Rikke Sørensen; Steen Z Abildstrom; Peter Weeke; Emil L Fosbøl; Fredrik Folke; Morten L Hansen; Peter R Hansen; Jan K Madsen; Ulrik Abildgaard; Lars Køber; Henrik E Poulsen; Christian Torp-Pedersen; Gunnar H Gislason Journal: BMC Cardiovasc Disord Date: 2010-01-29 Impact factor: 2.298